Scarica l'app Stockscreener
48.78
3.35%
-1.69
Dopo l'orario di chiusura:
49.96
1.18
+2.42%
Precedente Chiudi:
$50.47
Aprire:
$51.09
Volume 24 ore:
1.72M
Relative Volume:
0.57
Capitalizzazione di mercato:
$7.12B
Reddito:
$10.73M
Utile/perdita netta:
$-455.74M
Rapporto P/E:
-13.71
EPS:
-3.5569
Flusso di cassa netto:
$-502.70M
1 W Prestazione:
-3.92%
1M Prestazione:
+17.71%
6M Prestazione:
+89.36%
1 anno Prestazione:
-0.33%
Intervallo 1D:
$48.21
$51.79
Intervallo di 1 settimana:
$46.75
$52.17
Portata 52W:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta RNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
48.78 | 7.02B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Roth Capital | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Bernstein | Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Avidity reports positive pre-BLA meeting on Duchenne muscular dystrophy asset del-zota - MSN
What momentum shifts mean for Avidity Biosciences Inc.Insider Buying & Reliable Breakout Forecasts - newser.com
Oct 21 panel: Avidity Biosciences to speak at Chardan Conference; webcast available 11:00 PT - Stock Titan
Can Avidity Biosciences Inc. stock beat market expectations this quarterNew Guidance & Free Expert Approved Momentum Trade Ideas - newser.com
Sector ETF performance correlation with Avidity Biosciences Inc.Trade Ideas & Weekly Top Gainers Trade List - newser.com
How Avidity Biosciences Inc. stock performs in weak economy2025 Biggest Moves & AI Driven Stock Reports - newser.com
Forecasting Avidity Biosciences Inc. price range with options data2025 EndofYear Setup & High Return Stock Watch Alerts - newser.com
Using R and stats models for Avidity Biosciences Inc. forecasting2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Avidity Biosciences Delays Biologics License Application - TipRanks
Avidity Biosciences Updates BLA Submission Timeline for Del-Zota - TradingView
Will a bounce in Avidity Biosciences Inc. offer an exitWeekly Trade Summary & Weekly Hot Stock Watchlists - newser.com
Avidity Biosciences delays DMD drug submission to Q1 2026 By Investing.com - Investing.com Nigeria
Avidity rises on plans to submit muscle wasting drug application to US FDA - TradingView
Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission - MarketScreener
Avidity Biosciences delays DMD drug submission to Q1 2026 - Investing.com India
Avidity Biosciences announces positive pre-BLA meeting with US FDA for del-zota in DMD44 - MarketScreener
2025-10-13 | Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | NDAQ:RNA | Press Release - Stockhouse
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 - Sahm
How Avidity Biosciences Inc. stock compares to growth peersQuarterly Profit Review & Safe Entry Trade Reports - newser.com
What Makes Avidity Biosciences (RNA) an Investment Choice? - Yahoo Finance
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring a 36.85% Potential Upside in Innovative RNA Therapeutics - DirectorsTalk Interviews
Chart based exit strategy for Avidity Biosciences Inc.Market Growth Review & Low Risk Entry Point Tips - newser.com
Avidity Biosciences Inc. stock daily chart insightsGap Down & Weekly Top Performers Watchlists - newser.com
Can Avidity Biosciences Inc. stock hit record highs againPortfolio Value Report & Low Risk High Win Rate Stock Picks - newser.com
Avidity Biosciences (NASDAQ:RNA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Ranking Avidity Biosciences Inc. among high performing stocks via toolsWeekly Stock Recap & Weekly High Momentum Picks - newser.com
Is Avidity Biosciences Inc a good long term investmentMid Cap Growth Trends & Low Entry Capital Stocks - earlytimes.in
What drives Ball Corporation stock priceBlue Chip Stock Analysis & High Return Trading Portfolio - earlytimes.in
Avidity Biosciences’ Phase 2 Study on AOC 1001: A Potential Game-Changer for DM1 Treatment - TipRanks
Avidity Biosciences (NASDAQ:RNA) Insider Eric Mosbrooker Sells 6,562 Shares - MarketBeat
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society - BioSpace
Avidity Biosciences (RNA): Assessing Valuation Following Recent Positive Share Price Momentum - Yahoo Finance
Avidity Poised For Commercialization Transformation - San Diego Business Journal
Quantitative breakdown of Avidity Biosciences Inc. recent move2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
Avidity Biosciences Inc. stock trendline breakdownPortfolio Value Report & Free Weekly Watchlist of Top Performers - newser.com
Reversal of disease progression after 1 year — Avidity's del-zota EXPLORE44 data at WMS Oct 7-11 - Stock Titan
Avidity Biosciences Inc Stock Analysis and ForecastStock Price Targets & 5 Stocks Every Investor Should Own - earlytimes.in
Combining machine learning predictions for Avidity Biosciences Inc.Buy Signal & Fast Moving Stock Watchlists - newser.com
Relative strength of Avidity Biosciences Inc. in sector analysisJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avidity Biosciences Stock Price, Quotes and Forecasts | NASDAQ:RNA - Benzinga
BofA Securities Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
Can Avidity Biosciences Inc. hit a new high this monthEarnings Summary Report & Weekly Market Pulse Updates - newser.com
Real time scanner hits for Avidity Biosciences Inc. explainedBull Run & Technical Entry and Exit Alerts - newser.com
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Avidity Biosciences Inc Azioni (RNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Sale |
45.38 |
6,562 |
297,771 |
55,000 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Option Exercise |
10.16 |
2,208 |
22,433 |
41,075 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Sale |
40.58 |
2,208 |
89,601 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Option Exercise |
22.34 |
15,000 |
335,100 |
112,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Sale |
41.41 |
15,000 |
621,142 |
97,130 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Option Exercise |
6.57 |
1,542 |
10,131 |
40,409 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Sale |
45.41 |
1,542 |
70,022 |
38,867 |
| Flanagan W. Michael | Chief Scientific Officer |
Sep 11 '25 |
Option Exercise |
14.22 |
20,000 |
284,400 |
100,195 |
| Flanagan W. Michael | Chief Scientific Officer |
Sep 11 '25 |
Sale |
38.94 |
20,000 |
778,702 |
80,195 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):